[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumoconiosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumoconiosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,70,93,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100461402","phase-3-efficacy-and-safety-of-pirfenidone-capsules-in-the-treatment-of-pneumoconiosis-100461402",false,"NCT05288179","Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis","A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial of Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis","Inclusion Criteria:\n\n* 1\\. Age 18\\~70 years old (including 18 years old and 70 years old), gender is not limited.\n\n  2\\. Diagnosed with silicosis or coal worker's pneumoconiosis, in line with GBZ 70-2015 \"Diagnosis of Occupational Pneumoconiosis\".\n\n  3\\. Forced vital capacity at screening percentage of predicted value %FVC≥40% and \\\u003C80% 4. The percentage of carbon monoxide dispersion in the predicted value at the time of screening %DLCO≥30% and \\\u003C80%.\n\n  5.HRCT at screening showed diffuse interstitial changes in the lungs. 6. Patients voluntarily participated in this trial, with good compliance, and had the ability to understand and sign informed consent before the study.\n\nExclusion Criteria:\n\n* 1\\. Those who do not meet any of the inclusion criteria. 2. Those who have received lung lavage therapy within 3 months and plan to receive lung lavage therapy during the trial.\n\n  3\\. ALT or AST \\> 3 times ULN. 4. TBiL \\> 2 times ULN. 5. Creatinine clearance \\\u003C30 mL\u002Fmin. 6. Patients with co-infection or high fever within 4 weeks prior to screening, including but not limited to acute bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis.\n\n  7\\. Combined with tuberculosis or lung cancer. 8. Significant pulmonary arterial hypertension requiring parenteral therapy with epoprostenol\u002Ftreprostinil or severe right heart failure determined by the investigator to be unsuitable to participate in the trial.\n\n  9\\. Severe cardiovascular disease with one of the following conditions:\n  1. Severe hypertension within 6 weeks and uncontrolled with treatment (≥160\u002F100 mmHg);\n  2. Myocardial infarction within 6 months;\n  3. Unstable angina within 6 months. 10. Coagulation parameters: International normalized ratio (INR) \\> 2, prothrombin time (PT) prolongation \\> 1.5 times ULN.\n\n     11\\. Other conditions or comorbidities that may interfere with testing procedures (eg, intolerance to interruption of supplemental oxygen during pulmonary function tests) or, based on the investigator's judgment, that may interfere with trial participation or that may put patients at risk.\n\n     12\\. Patients with dysphagia or clinical signs of malabsorption or who require parenteral nutrition.\n\n     13\\. With active peptic ulcer. 14. History of thrombotic events (including stroke and transient ischemic attack) within 12 months.\n\n     15\\. Use of cytotoxic drugs, immunosuppressive drugs, cytokine-modulating drugs, or receptor antagonist drugs such as azathioprine, cyclophosphamide, cyclosporine, etanercept, infliximab, white Triene antagonists, methotrexate, tacrolimus, TNF-α inhibitors and tyrosine kinase inhibitors TKIs and other drugs.\n\n     16\\. Use of interferon, bisbenzylisoquinoline alkaloids (tetrandrine), polyethylene pyrimidine nitroxide (gramsilpine), quinape phosphate, hydroxyquinoline phosphate, aluminum citrate within 1 month before randomization , nintedanib, or high-dose acetylcysteine.\n\n     17\\. Patients who have previously used drugs that may cause pulmonary fibrosis, such as amiodarone, or have been exposed to asbestos, beryllium and other substances, or exposed to radioactive environments.\n\n     18\\. Hypersensitivity to the investigational drug or its components (eg, lactose).\n\n     19\\. Investigator judges that life expectancy due to other medical conditions is \\\u003C 2.5 years.\n\n     20\\. Major surgery planned during treatment. 21. Women who were pregnant, breastfeeding, or planning to become pregnant during the trial.\n\n     22\\. Women of childbearing age who are unwilling or unable to use a highly effective method of contraception during the 28 days before or 3 months after dosing.\n\n     23\\. According to the researcher, the patient is either alcohol or drug abuser. 24. mentally ill. 25. Those who participated in clinical trials of other drugs within 3 months. 26. Investigators judged to be unfit to participate in the trial.","ALL","18 Years","70 Years",{"count":20,"type":21},272,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is a randomized, double-blind, placebo-controlled, multicenter clinical study.\n\nThe main purpose of this study was to confirm the efficacy and safety of pirfenidone capsules in the treatment of pneumoconiosis.",[27],"Pneumoconiosis","RECRUITING","2025-11-19",{"date":31,"type":32},"2025-11-24","ACTUAL",{"date":34,"type":32},"2022-06-07",{"date":36,"type":21},"2026-09-30",{"name":38,"class":39},"Beijing Continent Pharmaceutical Co, Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100606640","phase-2-evaluating-the-efficacy-and-safety-of-modified-qing-zao-jiu-fei-decoction-on-pneumoconiosis-patients-100606640","NCT07178184","Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients","Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients: A Randomized, Double-blinded, Placebo-Controlled Trial","Inclusion criteria\n\n1. Aged 20-85;\n2. Patients with pneumoconiosis (Confirmed case of pneumoconiosis by Pneumoconiosis compensation fund board);\n3. Agree to undergo blood test and willing to complete questionnaires and take medication as scheduled; and\n4. Willing to provide written informed consent.\n\nExclusion criteria\n\n1. Patient with the following Chinese medicine syndromes\u002Fpatterns according to Chinese medicine theory: dampness, lung deficiency and coldness, or Yang deficiency according to Chinese medicine theory;\n2. Patients receiving Chinese medicine in a regular pattern within the past 2 weeks;\n3. Patients with chronic co-morbidities such as other fibrotic lung diseases in addition to pneumoconiosis and\u002For co-existing heart disease;\n4. Patients with a medical history of malignancy within the past 5 years;\n5. Patients with a medical history of any serious diseases such as severe kidney and liver impairments, autoimmune disease, thyroid disease, Hodgkin's disease, lymphoma and leukemia;\n6. Patients with known severe cognitive and mental disorders;\n7. Documented pregnancy or lactation; or\n8. Patients allergic to the drug used in this study.","20 Years","85 Years",{"count":51,"type":21},80,[53],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled study to investigate the beneficial efficacy and safety of Chinese medicine formula Modified Qing Zao Jiu Fei Decoction (MQZJFD) on pneumoconiosis patients. Participants will be randomized into one of the two groups (MQZJFD treatment group or placebo control group), and both undergo a consultation process by the Chinese Medicine practitioner (CMP). Eligible participants will be randomized and receive either MQZJFD granules or placebo granules for 16 weeks followed by post-treatment visits at week 20. The study will last for 20 weeks with a treatment period of 16 weeks plus a follow-up period of 4 weeks.",[27],[57,58,27],"RCT","Chinese Medicine","NOT_YET_RECRUITING","2025-09-15",{"date":62,"type":32},"2025-09-17",{"date":64,"type":21},"2025-11-01",{"date":66,"type":21},"2027-04-30",{"name":68,"class":69},"Chinese University of Hong Kong","OTHER",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":40},"100598891","pneumoconiosis-and-dust-exposure-china-cohort-100598891","NCT07077382","Pneumoconiosis and Dust Exposure China Cohort","PANDECT","Inclusion Criteria:\n\n* Diagnosed as pneumoconiosis\n\nExclusion Criteria:\n\n* Incomplete occupational history information\n* Has participated in any interventional clinical research",true,{"count":79,"type":21},2000,"3 Years","OBSERVATIONAL","The primary objective of this study is to characterize the demographic and clinical features of patients with occupational pneumoconiosis (hereinafter referred to as pneumoconiosis) in China. Secondary objectives include: 1) to describe the natural course of pneumoconiosis; 2) to evaluate the prognosis of pneumoconiosis patients; and 3) to assess complications and comorbidities in pneumoconiosis patients.",[27],"2025-07-13",{"date":86,"type":32},"2025-07-22",{"date":88,"type":32},"2021-05-28",{"date":90,"type":21},"2030-05-31",{"name":92,"class":69},"China-Japan Friendship Hospital",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":113,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100467364","early-phase-1-fapi-pet-for-lung-fibrosis-100467364","NCT05365802","FAPI PET for Lung Fibrosis","PET Study of 68Ga-FAPi-46 in Patients With Interstitial Lung Disease: an Exploratory Biodistribution Study With Histopathology Validation.","FAPI ILD","Inclusion criteria\n\n* Patients with ILD confirmed by CT at time of staging\n* Patients who have initiated or will initiate a new ILD medication with 3 months of enrollment OR Patients who are scheduled to undergo tissue biopsy or surgery of the lung\n* Patients are ≥ 18 years old at the time of the radiotracer administration\n* Patient can provide written informed consent\n\nExclusion criteria\n\n* Patient is pregnant or nursing\n* Patients with active infectious lung disease\n* Patients not expected to comply with the protocol requirements, not able to understand or follow trial procedures",{"count":102,"type":21},30,[104],"EARLY_PHASE1","This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD).\n\nThe purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease.\n\nThe study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung.\n\nThe study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview.\n\nParticipants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET\u002FCT scan and one High Resolution CT of the lungs.\n\nThe study is sponsored by Ahmanson Translational Theranostic Division at UCLA.",[107,108,109,110,111,27,112],"Interstitial Lung Disease","Idiopathic Interstitial Pneumonias","Drug-Induced Pneumonitis","Hypersensitivity Pneumonitis","Radiation Pneumonitis","Pulmonary Fibrosis",[114,115,116],"interstitial lung disease","pulmonary fibrosis","68Ga-FAPi-46","2025-06-30",{"date":119,"type":32},"2025-07-03",{"date":121,"type":32},"2021-11-16",{"date":123,"type":21},"2026-12",{"name":125,"class":69},"University of California, Los Angeles",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":40},"100559403","acceptance-based-healthy-lifestyles-program-for-patients-with-pneumoconiosis-100559403","NCT06563674","Acceptance-based Healthy Lifestyles Program for Patients With Pneumoconiosis","Nurse-led Acceptance-based Healthy Lifestyles Program for Community-dwelling Patients With Pneumoconiosis: A Waitlist Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Ethnic Chinese who is able read and speak Chinese.\n2. Adults aged 18 or over.\n3. Taking compensation for pneumoconiosis.\n\nExclusion Criteria:\n\n1. Those who have mental, visual, hearing, or cognitive impairments with regular medical follow-ups and treatment.\n2. Those who are unable to give written consent.",{"count":51,"type":21},[135],"NA","Symptoms, such as cough and shortness of breath, are common among patients with pneumoconiosis. Depression and anxiety can be elicited by the symptoms, while avoidance of daily activities is believed to reduce trigger of symptoms. The lung function is then declined and the risk of having stroke and heart failure is increased. The objectives of this 2-arm waitlist pilot randomized controlled trial are to test the effects and feasibility of an acceptance-based educational program among patients with pneumoconiosis. 80 participants will be recruited from community centers and randomly assigned to intervention group or waitlist-control group in a ratio of 1:1. The 6-week group-based educational program will be provided to the intervention group first, then the waitlist-control group. The program consists of 4 sessions integrated with acceptance components and care of pneumoconiosis. Their psychological health, healthy lifestyles, and cardiometabolic profiles will be assessed at baseline, week 6, and week 14. Data will be analyzed using a statistical package. The feasibility of the program will be evaluated by interview. The findings of this study can inform the integration of acceptance-based intervention into pneumoconiosis management in Hong Kong, and future study on chronic progressive lung diseases.",[27,138],"Healthy Lifestyle",[27,138,140],"Acceptance-based","2025-04-09",{"date":143,"type":32},"2025-04-13",{"date":145,"type":32},"2024-11-01",{"date":147,"type":21},"2026-01",{"name":68,"class":69}]